Yechiel Engelhard, MD, MBA

Building the new grid for AI health

[Yechiel Engelhard, MD, MBA @engelhardy]

Colorado repealed the first US state AI law before it even took effect, and the FDA keeps easing up on clinical AI.

When regulators step back, the liability doesn't vanish. It lands on the hospital that deployed the tool. Most can't even list what they're running.

[Yechiel Engelhard, MD, MBA @engelhardy]

@hsCIO Full panel discussion here: https://t.co/3PLnFfR6Mw

[Yechiel Engelhard, MD, MBA @engelhardy]

Four hospital security leaders, one panel, same conclusion: you can't protect what you can't see.

As a physician this is crazy - We'd never deploy a medical device and then stop checking if it works. But that's where health systems are with AI right now!
Visibility first. @hsCIO

[Yechiel Engelhard, MD, MBA @engelhardy]

Please stop telling me about your amazing vibe coding and everything you can now build internally for your company.

[Yechiel Engelhard, MD, MBA @engelhardy]

9/9 I hope the industry will learn from Teva's Digihaler story. Incorporating innovation effectively in pharma can transform healthcare, ensuring tech fulfills its promise to empower patients and providers. #DigitalHealth #Pharma #HealthcareTech

*only public observations*

[Yechiel Engelhard, MD, MBA @engelhardy]

7/9 Pharma needs to add leaders who know how to make tech a core part of the business, tech go-to-market strategies, pricing models, distribution channels, and long-term support for R&D.

[Yechiel Engelhard, MD, MBA @engelhardy]

8/9 To maximize impact, digital solutions should not rely solely on payer reimbursement. Diversifying revenue models while engaging patients, providers, and payers directly is crucial.

[Yechiel Engelhard, MD, MBA @engelhardy]

6/9 Pharma's tendency to see digital tools as 'add-ons' leads to underutilization. Drug-centric models miss tech's potential to provide significant clinical and economic value when positioned appropriately.

[Yechiel Engelhard, MD, MBA @engelhardy]

5/9 The observed gap between prescriptions and app downloads signals a misalignment between digital product teams and the brand. Pharma relies on traditional KPIs like prescriptions, missing how tech can redefine treatment, marketing, and pricing.

[Yechiel Engelhard, MD, MBA @engelhardy]

4/9 Pharma leaders often lack a deep understanding of tech beyond buzzwords and struggle with commercialization. They rely heavily on consultants and tech partnerships for compliance and security while attempting market strategy without a solid long-term plan.

[Yechiel Engelhard, MD, MBA @engelhardy]

3/9 Despite its potential to transform care, high prices ($239-$449) and limited insurance coverage were barriers, preventing adoption. The Digihaler journey shows that even when complex regulatory, privacy, and clinical needs are met, innovative effective solutions end too soon.

[Yechiel Engelhard, MD, MBA @engelhardy]

2/9 Digihalers empowered asthma patients using Bluetooth-enabled, ML data-driven tools to improve adherence and collaboration with healthcare providers. The FDA-approved suite set a precedent for integrating clinically proven tech.
https://t.co/zRWWpQXAXE

[Yechiel Engelhard, MD, MBA @engelhardy]

1/9 As founder of Gecko Health (acq. by Teva in 2015), I led Teva's Digital Health and launched the Digihaler portfolio until I left in ‘19. It's heartbreaking to see the team and portfolio shut down. The story reflects issues in pharma's tech integration. https://t.co/DF96k3DP04

[Yechiel Engelhard, MD, MBA @engelhardy]

6/ Looking ahead, the industry must adapt to advanced analytics and targeted multichannel strategies. How do you see the next generation of pharma marketing taking shape, and what role will GenAI play in redefining the space?💡 #PharmaStrategy

[Yechiel Engelhard, MD, MBA @engelhardy]

4/ Regulatory constraints from the FDA certainly play a role, but they don't fully explain the industry's slow pivot to digital and targeted marketing. How can pharma companies break free from traditional molds to leverage advanced analytics for better patient engagement?

[Yechiel Engelhard, MD, MBA @engelhardy]

5/ With DTC models gaining traction, it's crucial for pharma to reassess their marketing strategies. This involves a clear understanding of CAC across different channels and different uses, driving necessary shifts towards more personalized and efficient marketing. #DTCMarketing

[Yechiel Engelhard, MD, MBA @engelhardy]

3/ While TV ads have broad reach, their impact on actual consumer behavior and ROI remains murky. The industry lacks concrete benchmarks for CAC, especially in more innovative DTC and off-label campaigns. Isn't it time for a data-driven approach? #ROI #DigitalMarketing

[Yechiel Engelhard, MD, MBA @engelhardy]

2/Source:
https://t.co/2d2xWoUZfU

[Yechiel Engelhard, MD, MBA @engelhardy]

1/ We've learned to tune out the endless stream of TV ads from pharma, yet in 2023 over $1.5B was poured into these campaigns for weight loss & diabetes meds. Despite the massive spend, there's a startling lack of innovation in customer acquisition strategies. #PharmaMarketing

[Yechiel Engelhard, MD, MBA @engelhardy]

@HafengHalavan @MayaKidon @obaumer @derspigel Creepy but genius.